［1］GILLISON ML,CHATURVEDI AK,ANDERSON WF,et al.Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma［J］.J Clin Oncol,2015,33(29):3235-3242.
［2］GILLISON ML,AKAGI K,XIAO W,et al.Human papillomavirus and the landscape of secondary genetic alterations in oral cancers［J］.Genome Research,2019，29(1)：1-17.
［3］FAKHRY C,WESTRA WH,WANG SJ,et al.The prognostic role of sex,race,and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer ［J］.Cancer,2017,123(9):1566-1575.
［4］AGALLIU I,GAPSTUR S,CHEN Z,et al.Associations of oral α-,β-,and γ-human papillomavirus types with risk of incident head and neck cancer［J］.JAMA Oncology,2016,2(5):599-606.
［5］CASTELLSAGUE X,ALEMANY L,QUER M,et al.HPV involvement in head and neck cancers:comprehensive assessment of biomarkers in 3680 patients［J］.J Natl Cancer Inst,2016,108(6):djv403.
［6］彭燕燕,马锦霞,陈乐川,等.HPV与口咽部恶性肿瘤发病的相关性研究［J］.黑龙江医药,2017,30(6)：1201-1203.
PENG YY,MA JX,CHEN LC,et al.Study on the correlation between HPV and pharyngeal malignancy［J］.Heilongjiang Medicine Journal,2017,30(6)：1201-1203.
［7］马锦霞,郑景,彭燕燕,等.高危16和18型人乳头瘤病毒感染与口咽癌的相关性［J］.中国校医,2017,31(10):735-736.
MA JX,ZHENG J,PENG YY,et al.Correlation between high risk HPV-16 and HPV-18 infection and oropharyngeal cancer［J］.Chin J School Doctor,2017,31(10):735-736.
［8］张轶雯,钟里科,楼倩雯,等.基于GEO数据库的HPV阳性口咽癌特征基因生物信息学研究［J］.中国现代应用药学,2018,35(5):638-641.
ZHANG YW,ZHONG LK,LOU QW,et al.Study on the HPV-positive oropharyngeal cancer features gene based on GEO database by bioinformatics［J］.Chin J Mod Appl Pharm,2018,35(5):638-641.
［9］FARHOUD FARAJI,MUNFARID ZAIDI,CAROLE FAKHRY,et al.Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer［J］.Microbes and infection,2017,19(9/10):464-475.
［10］SPEEL EJ.HPV integration in head and neck squamous cell carcinomas:Cause and consequence［J］.Recent Results Cancer Res,2017,206:57-72.
［11］LEWIS JS,BEADLE B,BISHOP JA,et al.Human papillomavirus testing in head and neck carcinomas:Guideline from the college of american pathologists［J］.Archives of Pathology & Laboratory Medicine,2018,142(5):559-597.
［12］JORDAN RC,LINGEN MW,PEREZ-ORDONEZ B,et al.Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials［J］.The American Journal of Surgical Pathology,2012,36(7):945-954.
［13］PRIGGE E,ARBYN M,VON K,et al.Diagnostic accuracy of p16(INK4a) immunohistochemistry in oropharyngeal squamous cell carcinomas:A systematic review and meta-analysis［J］.International Journal of Cancer,2016,140(5):1186-1198.
［14］李武,赵九洲,王志中,等.不同方法检测口咽鳞癌中高危型HPV的感染情况分析［J］.肿瘤学杂志,2018,24(06):568-572.
LI W,ZHAO JZ,WANG ZZ,et al.Detection of high-risk HPV infection in oropharyngeal squa-mous cell carcinoma with various methods［J］.Journal of Chinese Oncology,2018,24(06):568-572.
［15］Chinese Society of Clinical Oncology(CSCO).Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)［J］.Chin J Cancer Res,2019,31(1):84-98.
［16］FAKHRY C,ZZNG Q,GILLISON M,et al.Prognostic groups for p16-positive oropharyngeal squamous cell cancer (p16-OPSCC) treated with chemoradiation therapy (CRT) in NRG Oncology/RTOG 0129 and 0522［J］.International Journal of Radiation Oncology,Biology,Physics,2016,94(4):873-874.
［17］PHUC FELIX,NGUYEN-TAN,QIANG ZHANG,et al.Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial:Long-term report of efficacy and toxicity［J］.Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2014,32(34):3858-3866.
［18］FAKHRY C,ZHANG Q,NGUYEN-TAN PF,et al.Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer［J］.Journal of Clinical Oncology,2017,35(36):4057-4065.
［19］COORDES A,LENZ K,QIAN X,et al.Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status［J］.European Archives of Oto-Rhino-Laryngology,2016,273(8):2157-2169.
［20］AMIN MB,EDGE SB,GREENE F,et al.AJCC cancer staging manual［M］.8th ed.New York:Springer,2017:113-121.
［21］ COLEVAS AD,YOM SS,PFISTER DG,et al.NCCN guidelines insights:Head and neck cancers,version 1.2018［J］.Journal of the National Comprehensive Cancer Network:JNCCN,2018,16(5):479-490.
［22］National Comprehensive Cancer Network.(NCCN)Clinical practice guidelines in oncology.Head and neck cancers,version 1.2019 ［EB/OL］.https://www.nccn.org/professionals/physician_gls/default.aspx.Accessed March 6,2019.In.
［23］PSYRRI A,RAMPIAS T,VERMORKEN JB.The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck［J］.Annals of Oncology,2014,25(11):2101-2115.
［24］CHERAGHLOU S,YU PK,OTREMBA MD,et al.Treatment deintensification in human papillomavirus-positive oropharynx cancer:Outcomes from the National Cancer Data Base［J］.Cancer,2018,124(4):717-726.
［25］WIRTH LJ,BURTNESS B,NATHAN CO,et al.Point/counterpoint:Do we de-escalate treatment of HPV-associated oropharynx cancer now? and how［J］.Am Soc Clin Oncol Educ Book,2019,39:364-372.
［26］MARUR S,LI S,CMELAK AJ,et al.E1308:Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group［J］.Journal of Clinical Oncology,2017,35(5):490-497.
［27］CHEN AM,FELIX C,WANG PC,et al.Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx:a single-arm,phase 2 study［J］.The Lancet Oncology,2017,18(6)：803-811.
［28］HEGDE JV,SHAVERDIAN N,DALY ME,et al.(P074) Patient-reported quality of life outcomes after de-escalated chemoradiation for HPV-positive oropharyngeal carcinoma:Findings from a phase II trial［J］.International Journal of Radiation Oncology,Biology,Physics,2017,98(2):E35.
［29］GILLISON ML,TROTTI AM,HARRIS J,et al.Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016):a randomised,multicentre,non-inferiority trial［J］.The Lancet,2019,393(10166):40-50.
［30］MEHANNA H,ROBINSON M,HARTLEY A,et al.Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV):An open-label randomised controlled phase 3 trial［J］.The Lancet,2019,393(10166):51-60.
［31］LYFORD-PIKE S,PENG S,YOUNG GD,et al.Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma［J］.Cancer Res,2013，73(6)：1733-1741.
［32］HERRERO R,QUINT W,HILDESHEIM A,et al.Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in costa rica［J］.PLOS ONE,2013,8(7):e68329.
［33］CHATURVEDI AK,GRAUBARD BI,BROUTIAN T,et al.Effect of prophylactic human papillomavirus (HPV) vaccination on Oral HPV infections among young adults in the united states［J］.Journal of Clinical Oncology,2018,36(3):262-267.
［34］ CUBURU N,SCHILLER JT.Moving forward with human papillomavirus immunotherapies［J］.Human Vaccines & Immunotherapeutics,2016,12(11):2875-2880.